Sinopharm Tech Holdings Limited

As of December 31, 2023, Sinopharm Tech Holdings Limited carries a market capitalization of 24.25M, placing it among publicly traded companies globally. Its enterprise value stands at 19.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2023, Sinopharm Tech Holdings Limited has 183.69M shares outstanding.

These figures are as of December 31, 2023. The price-to-sales ratio is 0.52, and the price-to-book ratio stands at -0.14.

These figures are as of December 31, 2023. The EV/Sales ratio of 0.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 19.56M versus a market cap of 24.25M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2023, Sinopharm Tech Holdings Limited maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -5.48, indicating conservative leverage, while an interest coverage ratio of -18.26 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -57.54, reflecting losses generated across the asset base. The company generates approximately 2.10M in revenue per employee across its workforce of 22.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.65 indicates how many times Sinopharm Tech Holdings Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2023, Sinopharm Tech Holdings Limited recorded an income tax benefit of -1.31M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -29.41M and -28.92M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Sinopharm Tech Holdings Limited's stock has declined approximately 27.87% over the past 52 weeks. The 50-day moving average sits at 0.20, while the 200-day moving average is 0.25.

Over the twelve months ended December 31, 2023, Sinopharm Tech Holdings Limited generated 46.66M in revenue and converted that into -28.92M in net income, yielding earnings per share of -0.15. EBITDA reached -117.93M, while operating income came in at -11.32M.

As of December 31, 2023, Sinopharm Tech Holdings Limited holds 8.51M in cash and equivalents against 10.00M in total debt, resulting in a net debt position of 1.50M. Total book value stands at -176.32M, with working capital of -192.04M providing operational flexibility.

Over the twelve months ended December 31, 2023, Sinopharm Tech Holdings Limited posted a gross margin of 11.90, reflecting its pricing power and cost economics. The operating margin of -24.27 and net profit margin of -61.98 provide insight into operational efficiency.

Sinopharm Tech Holdings Limited's most recent stock split took place on September 12, 2023 with a 25:1 split ratio.

As of December 31, 2023, Sinopharm Tech Holdings Limited has an Altman Z-Score of -102.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.